ASCO: Ivonescimab A New Challenger To Keytruda In 1L, PD-L1-High NSCLC?

Akeso/Summit Release New Head-To-Head Results

 
• By Dexter Jie Yan
lung cancer
Akeso/Summit contender may challenge Keytruda in PD-L1-high NSCLC • Source: Shutterstock

More from China

More from Focus On Asia